Updates

Author Details

Joe Pierce

May 18, 2020May 14, 2020
Visiting a Loved One with Dementia Requires a Delicate Balance

Something as simple as an overnight visitor or a dinner guest can send a person with Alzheimer’s disease into a bit of a tailspin. ... Read more
May 18, 2020May 18, 2020
PTI-125 Fails to Lower Alzheimer’s Protein Levels in Phase 2 Trial

Cassava Sciences‘s investigational therapy PTI-125 failed to significantly lower the levels of Alzheimer’s-relevant biomarkers present in fluid surrounding the brain and spinal cord of ... Read more
May 11, 2020May 7, 2020
Maintaining Brain Health Is Important for Future Cognitive Function

During the coronavirus pandemic, many people have posted on social media about their focus on good health via exercise. Turn on the news, and ... Read more
May 11, 2020May 11, 2020
Potential Agitation Treatment, AXS-05, Shows Efficacy and Safety in Phase 2/3 Trial

Axsome Therapeutics‘ investigational oral therapy AXS-05 significantly and rapidly lessened agitation in patients with Alzheimer’s disease, top-line results from a Phase 2/3 trial show. The therapy ... Read more
May 4, 2020May 4, 2020
Large Study Finds No Evidence That Low-dose Aspirin Reduces Alzheimer’s Risk

Taking daily low-dose aspirin does not seem to reduce the risk of dementia, cognitive decline, or Alzheimer’s disease, new clinical trial data show. The ... Read more

Subscribe to our mailing list

Get regular updates delivered to your email box.

Author Details

Joe Pierce

Thanks! Please check your email for a confirmation email.

November 8, 2017November 8, 2017

Anavex ‘Cautiously Optimistic’ After Noting Cognitive Improvement in Alzheimer’s Treatment

News

Anavex Life Sciences says its Alzheimer’s drug candidate Anavex 2-73 may have a role in treating the disease. Data from a long-term extension trial, although small, indicated that the therapy improved cognitive and functional measures in patients. According to data ... Read more

Visiting a Loved One with Dementia Requires a Delicate Balance

PTI-125 Fails to Lower Alzheimer’s Protein Levels in Phase 2 Trial

Maintaining Brain Health Is Important for Future Cognitive Function

Potential Agitation Treatment, AXS-05, Shows Efficacy and Safety in Phase 2/3 Trial

Large Study Finds No Evidence That Low-dose Aspirin Reduces Alzheimer’s Risk

Industry leaders seek to advance innovative resources for rare and orphan disease communities amid COVID-19 outbreak

Alzheimer’s Caregivers Often Fear Contracting the Disease

Surge in Telemedicine One ‘Good’ Outcome from COVID-19 Crisis, Doctors Say

FDA Filing of Alzheimer’s Therapy Aducanumab Delayed to Late 2020, Biogen Says

Anticipating Summer Solstice in Support of Alzheimer’s Funding

Lundbeck Sharing Data on Failed Idalopirdine Trials with Scientists via C-Path

Subscribe to our mailing list

Let’s Celebrate Togetherness While Flattening the Curve

Phase 2/3 Trial of Treatment for Agitation in Alzheimer’s to Conclude Early

More Telemedicine Is a Good Thing

At-home Activities Offered for Alzheimer’s Patients During COVID-19 Pandemic

Trial of Oral Anavex 2-73 in Early Alzheimer’s to Continue with Adjustments

Carrying On, with Empathy

Blood Pressure Treatment May Aid Cognition in Very Early Alzheimer’s

Moderate Drinking Linked to Lower Amyloid-Beta Levels, Study Says

Caregivers Are Battling on All Fronts to Shield Loved Ones from Pandemic

Taking Dantrium via Nose More Effective than by Mouth, Lowers Dose, Study Suggests

Half of Primary Physicians Say U.S. is Unprepared for Growing Alzheimer’s Demands

Amino Acid L-Serine May Reduce Memory Loss in Alzheimer’s Disease, Study Suggests

PSEN1 Gene Alteration May Be Early Biomarker for Alzheimer’s, Study Suggests

How Caregivers Can Protect Their Loved Ones from Coronavirus

Vermont Couple Shares Strategies on Managing Neurodegenerative Disease

Neurosteer Promotes Wearable Monitor to Detect Early Alzheimer’s

Blood Test Can Differentiate Alzheimer’s From Other Dementias, Research Suggests

Accessing Benefits Can Be Challenging for Parents with Alzheimer’s Disease

Sangamo, Biogen Team Up to Develop Gene Therapies for Neurological Diseases

Video: BioNews’ Social Media Campaign Highlights #WhatMakesMeRare

Early Onset Dementia, AD Diagnoses Rose 200% in 4 Years, BCBSA Report Finds

Temple Scientist Awarded $500K Grant to Advance Alzheimer’s Drug Discovery

Reliving Loss Is a Painful Cycle for People with Alzheimer’s

Cognitive Difficulties Can Predict Neurodegeneration, Study Finds

DNA from Bacteria in Brain May Promote Tau Clumping, Study Suggests

New Carbon Nanotube Sensor Ably Spots Alzheimer’s via Proteins in Blood, Study Reports

Phase 2 Trial into Potential Oral Alzheimer’s Treatment Safe to Continue, Independent Board Says

Should Loved Ones with Alzheimer’s Pitch in with Chores?

Solanezumab and Gantenerumab Fail to Slow Memory Loss or Cognitive Decline in Early-onset Alzheimer’s, Study Finds

Biogen to Start Re-dosing Aducanumab in Alzheimer’s Patients From Halted Trials

Number of Dementia Cases Likely to Double by 2050 as Europe Ages, Report Says

Pin It on Pinterest